Billion-dollar acquisition of Sobi fails

Private equity funds Advent and Aurora failed to achieve the needed support by investors in Sobi before the final and decisive deadline and will therefore not be acquiring the pharmaceutical firm.

Photo: John Ambrose / Sobi / PR

They came very close, but stumbled before the finish line.

Private equity funds Advent and Aurora are taking stock after the deadline has come and gone for accepting Swedish pharmaceutical firm Sobi's acquisition offer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs